Allarity Therapeutics vs Inovio Pharmaceuticals
ALLR and INO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLR and INO compare
Inovio Pharmaceuticals is the larger company, worth 13 times as much as Allarity Therapeutics ($169M against $13.4M).
Inovio Pharmaceuticals scores higher on the StockData Score (4 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLR | INO |
|---|---|---|
| Size and price | ||
| Market cap | $13.4M | $169M |
| Share price | $0.841 | $1.63 |
| Change, 1 year | −28.7% | −20.5% |
| Change, 5 years | – | −98.1% |
| Beta (5Y) | 1.46 | −0.26 |
| Employees | 8 | 27 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.8× (better) | 38.6× |
| FCF yield | – | −47.9% |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | – | −61.2% |
| Profitability | ||
| Return on equity | −157% (better) | −410% |
| Return on invested capital | −957% | – |
| Financial health | ||
| Debt / equity | 5.90 (better) | 0.00 |
| Interest coverage | −10.1× | – |
| Current ratio | 1.11 (better) | 1.00 |
| Altman Z-score | −6.65 (better) | −55.23 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | 6.6% (better) | −22.6% |
| Shareholder yield | 6.6% (better) | −22.6% |
| Ownership | ||
| Held by institutions | 8.1% | 31.7% |
| Held by insiders | 6.3% | 0.38% |
| Short interest, % of float | 1.5% | 21.5% |
Go deeper
- ALLR stock overview
- ALLR income statement
- ALLR valuation and score
- INO stock overview
- INO income statement
- INO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.